Compare Micron Technology, Inc. (MU) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Tempus AI — how do they compare? Micron Technology, Inc. trades at $1,030.29 (market cap $1.13T), while Tempus AI trades at $61.15 (market cap $11.67B). The key difference: Micron Technology, Inc. is far larger — about 96.8× Tempus AI's market cap, and Micron Technology, Inc. pays a 0.05% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| MU | TEM | |
|---|---|---|
Market Cap | $1.13T | $11.67B |
Sector | Technology | Broad Market / Factor |
52-Week High | $1.21K | $103.25 |
52-Week Low | $140.00 | $41.55 |
Enterprise Value | $1.11T | $12.30B |
Dividend Yield | 0.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,000.26, down 1.61% on the day, but remains in a bullish technical trend with strong analyst support. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $25.11 surpassing the $20.98 forecast. Fundamentals show robust growth, with 2025 revenue at $37.38 billion and net income margin of 55.91%. Positive sentiment is driven by AI-driven memory demand and projected 2026 revenue of $90.3 billion.
Outlook is bullish given memory supply constraints and AI tailwinds, but risks include cyclical industry volatility and high valuation multiples. The consensus price target is $1,540 with 82.9% of analysts rating it a buy. Investors should weigh strong cash flow growth against potential margin pressures if demand softens.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
